BDR Pharma to acquire stake in Acme’s oral solid formulations business

Existing investors, including private equity firm PAG, are selling their stakes in Acme's oral solids formulations business in a transaction that is expected to value the business at about $250 million.

Open True Mainstream to compare left, right, and center coverage

1,600+ newsrooms tracked, in English, around the clock. Real newsrooms only — no NGOs, no press releases. Left/Right tags come from reader feedback. No algorithmic feed.